FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Teva Pharmaceuticals Risedronate Sodium Delayed-release Tablets Recall

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (N…

Teva Pharmaceuticals USA · North Wales, PA

Risk level
Class III
Reported by FDA
Jan 25, 2017
Recall ID
D-0431-2017
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Risedronate Sodium Delayed-release Tablets starting Dec 1, 2016. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0431-2017 on Jan 25, 2017. Reason: Failed Dissolution Specifications. Status: Terminated.

Why it was recalled

Failed Dissolution Specifications

Product description

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Lot numbers, UPCs & expiration codes

Lot # 34027040A; Exp 10/17

Where it was sold

Nationwide in the USA and Puerto Rico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0431-2017
Classification
Class III
Status
Terminated
Recall initiated
Dec 1, 2016
FDA report date
Jan 25, 2017
Quantity
6,800 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA

Original FDA data

Every field from FDA enforcement report D-0431-2017, exactly as published.

Show all FDA fields
City
North Wales
State
PA
Status
Terminated
Country
United States
Event ID
75872
Address
1090 Horsham Rd
Code information
Lot # 34027040A; Exp 10/17
Postal code
19454-1505
Report date
Jan 25, 2017
Product type
Drugs
Recall number
D-0431-2017
Classification
Class III
Recalling firm
Teva Pharmaceuticals USA
Product quantity
6,800 cartons
Termination date
Jun 29, 2017
Reason for recall
Failed Dissolution Specifications
Voluntary / mandated
Voluntary: Firm initiated
Product description
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
Distribution pattern
Nationwide in the USA and Puerto Rico
Recall initiation date
Dec 1, 2016
Initial firm notification
Letter
Center classification date
Jan 13, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0431-2017, published Jan 25, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls